Samsung Pharmaceutical Co., Ltd. (KOSE:A001360) announced a private placement of unregistered and unsecured private convertible bonds for gross proceeds of KRW 15,100,000,000 on April 1, 2015. The company will issue 22nd domestic unregistered/unsecured private convertible bonds for KRW 10,100,000,000 and 23rd domestic unregistered/unsecured private convertible bonds for KRW 5,000,000,000. Each bond will mature on April 3, 2018.

The bonds issued will carry yield to maturity of 4% and zero coupon rate. The lump sum redemption will take place at the time of maturity. Each bond will be convertible into the common shares of the company at KRW 6,467 per share.

There will be 100% conversion. The transaction will include participation from nine new investors for 23rd domestic unregistered/unsecured private convertible bonds including, Future Creation Fund T.S. M&A 7 Investment Account, a fund managed by T.S. Investment Corporation for KRW 5,000,000,000, T.S. Investment Corporation for KRW 200,000,000, Duk-Soo Jang for KRW 1,000,000,000, Withwin Hybrid Fund No. 1 for KRW 1,000,000,000, OD Tech Co., Ltd. for KRW 1,000,000,000, TS 2015-9 Honam Chungcheong Fund for KRW 800,000,000, Lake Investment Advisors for KRW 500,000,000, Taek-Dong Kim for KRW 500,000,000, and Jae-Won Lee for KRW 100,000,000.

The transaction will include participation from an existing investor, GemVax & Kael Co., Ltd. for 23rd domestic unregistered/unsecured private convertible bonds for KRW 5,000,000,000.